The direct answer

Trevogrumab is an investigational antibody targeting myostatin. The COURAGE program has examined it alongside semaglutide, asking whether it can reduce the loss of lean tissue during weight loss.[1]

Class
Anti-myostatin antibody
Program
COURAGE
Source type
Sponsor report · Oct 2026

What is the research question?

The question is not simply whether body weight falls. It is whether a combination changes the composition of that weight loss. Regeneron reported new 52-week COURAGE results on October 1, 2026.[1]

That makes the population, background medicine, follow-up period, and measurement method central to the answer. A result observed during semaglutide treatment should not be described as a stand-alone result in healthy athletes.

What does “muscle preservation” mean here?

The sponsor report includes whole-body lean-mass measurements using DXA and thigh-muscle measurements in an MRI subgroup. Those are different measures. A headline percentage from one cannot substitute for the other.[1]

To interpret any preservation claim, ask what loss occurred in the comparison group, what loss remained in the treatment group, and whether the figure is an absolute change or a relative difference. Less loss is also different from a gain above baseline.

What is the evidence status?

The October release is a sponsor announcement of trial findings. It described conference presentation and a paper in press. Readers should look for the complete publication and any later updates before treating the announcement as a final account.[1]

A press release can identify an important result, but its purpose and level of detail differ from a full methods section, analysis plan, and adverse-event table. This is an evidence-format distinction, not a conclusion that the result is either true or false.

What should a useful summary include?

A clear summary names the treatment combination, labels the sponsor source, separates MRI from DXA, and explains the comparator. It also avoids claiming a functional benefit unless a functional measure supports one.

The COURAGE evidence note explains the reported results. For the broader differences between mechanisms, use the compound comparison.

Questions, answered.

Is trevogrumab a short peptide?

It is an antibody. The generic search phrase “myostatin peptide” does not identify its molecular class.

Does preservation mean that muscle increased?

Not necessarily. A group can lose less tissue than a comparison group while still ending below its own baseline.

Sources & further reading

Primary research and official records used for this page. Study results apply to the populations and interventions described.

  1. Phase 2 COURAGE Trial: 52-week trevogrumab findingsRegeneron · October 1, 2026 · Sponsor-reported results; distinct from a full paper
Educational information, not individualized medical advice. This article has not been independently reviewed by a clinician. Regulatory and research details are dated; check the linked primary records for subsequent changes.